{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/olecranon-bursitis/","result":{"data":{"firstChapter":{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field e4d9ed8d-2520-4d17-93d0-bdb9bd7193df --><h1>Olecranon bursitis: Summary</h1><!-- end field e4d9ed8d-2520-4d17-93d0-bdb9bd7193df -->","htmlStringContent":"<!-- begin item c202d4fc-7433-4926-811a-ae4a21e49104 --><!-- begin field 4fa4cfec-d2e2-4a2c-8b53-884a3fa991d6 --><ul><li>The olecranon bursa is a sac overlying the olecranon process of the elbow beneath the skin. It reduces friction on movement between the skin, tendons, ligaments, and bone, and allows them to glide smoothly over one another.</li><li>Bursitis occurs when the bursa is irritated and inflamed and is generally classified as:<ul><li>Non-septic (most common) — sterile inflammation resulting from various causes including trauma or overuse.</li><li>Septic — infection resulting from seeding of the bursal sac with micro-organisms, usually bacteria.</li></ul></li><li>Olecranon bursitis is more common in:<ul><li>Young or middle-aged men.</li><li>People in jobs which involve risk of regular elbow trauma or pressure on the bursa. For example gardeners and mechanics.</li><li>Athletes who play sports which involve repetitive overhead throwing or elbow flexion and extension.</li></ul></li><li>Most cases of olecranon bursitis resolve without complications; however, recurrent episodes may occur especially after recurrent minor trauma.</li><li>Olecranon bursitis should be suspected if:<ul><li>There is swelling over the elbow that appears over several hours to several days, may be tender or warm (but may be painless), and is fluctuant.</li><li>Movement at the elbow joint is painless except at full flexion when the swollen bursa is compressed.</li><li>There is a history of preceding trauma or bursal disease.</li><li>There is evidence of local skin abrasion.</li></ul></li><li>Management of olecranon bursitis includes:<ul><li>Advising on conservative measures (such as rest, compression bandaging, avoidance of trauma to the elbows, and analgesia) until symptoms improve.</li></ul></li><li>For non-septic bursitis management includes:<ul><li>Offering reassurance that most people will respond to conservative treatment.</li><li>Considering the need for aspiration, particularly if the effusion is large.</li><li>Considering the need for a corticosteroid injection into the bursa (if there is expertise and experience in performing this procedure).</li><li>Referral if there is no response to available treatments in primary care after 2 months.</li></ul></li><li>For septic bursitis management includes:<ul><li>Aspiration and treating empirically with flucloxacillin (or a macrolide if there is penicillin allergy) until culture results are known (then adjusting antibiotic accordingly).</li><li>Urgent referral should be arranged or specialist advice sought if there is no response, or an inadequate response to an antibiotic in septic bursitis, or complications are suspected.</li><li>Considering the need for repeated aspiration if swelling, tenderness, and erythema recur.</li><li>Managing any associated conditions, such as gout, rheumatoid arthritis, or cellulitis.</li></ul></li><li>Admission to hospital should be arranged urgently if the person has:<ul><li>A suspected septic joint (which presents with a limited range of movement of the elbow joint, unlike septic bursitis).</li><li>Septic bursitis and severe infection or systemic toxicity.</li></ul></li><li>Admission to hospital should be arranged on the same day if the person has septic bursitis and<ul><li>A pointing abscess requiring incision and drainage, if the expertise to perform this procedure is not available.</li><li>Extensive cellulitis</li></ul></li><li>Urgent referral should be made if the person experiences recurrent septic bursitis.</li><li>Referral should be considered if a person with non-septic bursitis (in whom septic bursitis has been excluded) does not respond after 2 months of conservative measures (referral should be arranged sooner if the symptoms are pronounced, e.g. there is significant discomfort).</li></ul><!-- end field 4fa4cfec-d2e2-4a2c-8b53-884a3fa991d6 --><!-- end item c202d4fc-7433-4926-811a-ae4a21e49104 -->","topic":{"id":"677058a2-327c-5c74-b020-fa294dc001d6","topicId":"2b5681b1-a6ac-486f-9c29-562f1d00c942","topicName":"Olecranon bursitis","slug":"olecranon-bursitis","aliases":[],"chapters":[{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5f6379bf-0c3e-5f36-b626-ae14f093855a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes"},{"id":"13cfdc08-b4d8-56a4-a5ac-0dfa1d7e6cfe","slug":"update","fullItemName":"Update"}]},{"id":"3f962ec9-103d-50a6-876c-4a47fb7de1c6","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"c7da3eeb-0643-5b34-ab2c-8ba9d3db1032","slug":"goals","fullItemName":"Goals"},{"id":"ce4821e2-3cc9-5e64-a68c-2347bb4c8b71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d54ee925-bde2-5a23-a8d7-5890790b3298","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55611326-78d9-5af9-a3d8-3243f894aff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"97a3cb4a-8ad1-5279-9a00-d3071c8afd3f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ae95433-ad22-5338-aab8-270312eb6fa0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9d59d92b-a3ce-5a17-ad08-8bdcd5032439","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"198864d0-53c2-5b2c-b236-08be4dd0177d","slug":"definition","fullItemName":"Definition"},{"id":"1c159260-37b3-563a-831f-16da306c92e0","slug":"causes","fullItemName":"Causes"},{"id":"83714e1b-4423-54d1-893d-80c2a92a842a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e2b0682f-f14b-5991-9d25-9d0a5572ae36","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a6ff79ed-b8bd-5dde-b777-048ebe2f83e8","slug":"complications","fullItemName":"Complications"}]},{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"1d3747f8-bed3-50aa-9617-789459b5adf6","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"653f7410-1fe1-5ae6-a30f-00e9b38f6285","slug":"aspiration","fullItemName":"Aspiration"}]},{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","slug":"management","fullItemName":"Management","subChapters":[{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"4cc6cfee-67bb-5942-a9b4-d95ff1d2b51a","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"004b3dea-95a9-59e3-8f0e-2c801e5ebb1a","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"06e783b5-d47f-55ea-b7be-a3cbd73f4ddb","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"1fb7925d-db93-5872-9164-840da5cf1d91","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6a47a3d4-5551-565a-a0f6-618797e318a7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8a12dab5-123e-505b-bb29-69626a4ef54e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3600086-ecd1-5ccd-9711-0f1444616612","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87436259-d98d-5e39-ba2d-28c6133751e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5c35d7b1-2c5b-5fd5-9de1-d0a85c2d7931","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"677058a2-327c-5c74-b020-fa294dc001d6","topicId":"2b5681b1-a6ac-486f-9c29-562f1d00c942","topicName":"Olecranon bursitis","slug":"olecranon-bursitis","aliases":[],"topicSummary":"The olecranon bursa is a sac overlying the olecranon process of the elbow beneath the skin.","lastRevised":"Last revised in January 2021","nextPlannedReviewBy":"2021-09-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2021-08","nextPlannedReviewByDisplay":"August 2021","specialities":[{"id":"f8332083-731e-50fe-a895-030315ce6083","name":"Musculoskeletal","slug":"musculoskeletal"}],"chapters":[{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5f6379bf-0c3e-5f36-b626-ae14f093855a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes"},{"id":"13cfdc08-b4d8-56a4-a5ac-0dfa1d7e6cfe","slug":"update","fullItemName":"Update"}]},{"id":"3f962ec9-103d-50a6-876c-4a47fb7de1c6","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"c7da3eeb-0643-5b34-ab2c-8ba9d3db1032","slug":"goals","fullItemName":"Goals"},{"id":"ce4821e2-3cc9-5e64-a68c-2347bb4c8b71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d54ee925-bde2-5a23-a8d7-5890790b3298","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55611326-78d9-5af9-a3d8-3243f894aff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"97a3cb4a-8ad1-5279-9a00-d3071c8afd3f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ae95433-ad22-5338-aab8-270312eb6fa0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9d59d92b-a3ce-5a17-ad08-8bdcd5032439","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"198864d0-53c2-5b2c-b236-08be4dd0177d","slug":"definition","fullItemName":"Definition"},{"id":"1c159260-37b3-563a-831f-16da306c92e0","slug":"causes","fullItemName":"Causes"},{"id":"83714e1b-4423-54d1-893d-80c2a92a842a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e2b0682f-f14b-5991-9d25-9d0a5572ae36","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a6ff79ed-b8bd-5dde-b777-048ebe2f83e8","slug":"complications","fullItemName":"Complications"}]},{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"1d3747f8-bed3-50aa-9617-789459b5adf6","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"653f7410-1fe1-5ae6-a30f-00e9b38f6285","slug":"aspiration","fullItemName":"Aspiration"}]},{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","slug":"management","fullItemName":"Management","subChapters":[{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"4cc6cfee-67bb-5942-a9b4-d95ff1d2b51a","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"004b3dea-95a9-59e3-8f0e-2c801e5ebb1a","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"06e783b5-d47f-55ea-b7be-a3cbd73f4ddb","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"1fb7925d-db93-5872-9164-840da5cf1d91","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6a47a3d4-5551-565a-a0f6-618797e318a7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8a12dab5-123e-505b-bb29-69626a4ef54e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3600086-ecd1-5ccd-9711-0f1444616612","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87436259-d98d-5e39-ba2d-28c6133751e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5c35d7b1-2c5b-5fd5-9de1-d0a85c2d7931","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"677058a2-327c-5c74-b020-fa294dc001d6"}},"staticQueryHashes":["3666801979"]}